{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:32:28Z","timestamp":1791307948814,"version":"4.3.1"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2011,4,18]],"date-time":"2011-04-18T00:00:00Z","timestamp":1303084800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0018925","type":"journal-article","created":{"date-parts":[[2011,4,18]],"date-time":"2011-04-18T20:52:22Z","timestamp":1303159942000},"page":"e18925","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Imatinib Treatment Induces CD5+ B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia"],"prefix":"10.1371","volume":"6","author":[{"given":"Silvia","family":"Catellani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Pierri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Poggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Raffaella","family":"Zocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,4,18]]},"reference":[{"key":"ref1","first-page":"984","article-title":"National Comprehensive Cancer Network. NCCN: clinical practice guidelines in oncology. Chronic Myelogenous Leukemia.","volume":"Netw.7","author":"S O'Brien","year":"2009","journal-title":"J Natl Compr Canc"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukaemia.","volume":"23","author":"A Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1056\/NEJMcibr061878","article-title":"Imatinib Mesylate \u2013 Uncovering a fast track to adaptive immunity.","volume":"354","author":"MJ Smyth","year":"2006","journal-title":"New Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1172\/JCI21102","article-title":"Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.","volume":"114","author":"C Borg","year":"2004","journal-title":"J Clin Invest"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nm1352","article-title":"Interferon-producing killer dendritic cell provide a link between innate and adaptive immunity.","volume":"12","author":"CW Chan","year":"2006","journal-title":"Nature Medicine"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.canlet.2006.10.024","article-title":"Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts.","volume":"250","author":"L Mueller","year":"2007","journal-title":"Cancer Lett"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/eji.1830211105","article-title":"Terminal differentiation of human bone marrow cells capable of spontaneous and high-rate immunoglobulin secretion: role of bone marrow stromal cells and interleukin 6.","volume":"21","author":"E Roldan","year":"1991","journal-title":"Eur J Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1084\/jem.20020519","article-title":"Crosstalk between BCR\/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells.","volume":"196","author":"A Ptasznik","year":"2002","journal-title":"J Exp Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2004-08-2992","article-title":"Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells.","volume":"105","author":"G Muehlinghaus","year":"2005","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2141.2005.05443.x","article-title":"Bone marrow endothelial cells in multiple myeloma secrete CXC chemokines that mediate interactions with plasma cells.","volume":"129","author":"A Pellegrino","year":"2005","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/leu.2009.193","article-title":"Choosing the best treatment strategy for chronic myeloid leukaemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.","volume":"24","author":"E Jabbur","year":"2010","journal-title":"Leukemia"},{"key":"ref12","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.","volume":"2190-2196","author":"A Hochhaus","year":"2002","journal-title":"Leukemia 16;"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.","volume":"18","author":"A Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.","volume":"8","author":"JF Apperley","year":"2007","journal-title":"Lancet Oncology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase.","volume":"115","author":"HM Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1002\/eji.200636887","article-title":"CD5<sup>+<\/sup> B cells with the features of subepithelial B cells found in human tonsils.","volume":"37","author":"M Dono","year":"2007","journal-title":"Eur J Immunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0952-7915(00)00204-1","article-title":"B1 cells: similarities and differences with other B cell subsets.","volume":"13","author":"F Martin","year":"2001","journal-title":"Curr Opin Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"European LeukemiaNet. Chronic myeloid leukemia.","volume":"370","author":"R Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/intimm\/7.4.635","article-title":"T cell-induced B cell blasts differenziate into plasma cells when cultured on bone marrow stroma with IL-3 and IL-10.","volume":"7","author":"P Merville","year":"1995","journal-title":"Int Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.4049\/jimmunol.159.5.2085","article-title":"Memory, but not na\u00efve, peripheral blood B lymphocytes differentiate into Ig-secreting cells after CD40 ligation and co-stimulation with IL-4 and the differentiation factors IL-2. IL-10, and IL-3.","volume":"159","author":"V Kindler","year":"1997","journal-title":"J Immunol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.4049\/jimmunol.173.9.5361","article-title":"Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6.","volume":"173","author":"K Ozaki","year":"2004","journal-title":"J Immunol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"7867","DOI":"10.4049\/jimmunol.175.12.7867","article-title":"IL-21 induces differentiation of human na\u00efve and memory B cells into antibody-secreting plasma cells.","volume":"175","author":"R Ettinger","year":"2005","journal-title":"J Immunol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.molimm.2006.08.021","article-title":"VCAM-1 positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L and BAFF.","volume":"44","author":"DH Schaumann","year":"2007","journal-title":"Mol Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/0008-5472.CAN-07-5074","article-title":"A novel Bone morphogenetic protein signalling in heterotypic cell interactions in prostate cancer.","volume":"68","author":"S Yang","year":"2008","journal-title":"Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program.","volume":"17","author":"J Gabert","year":"2003","journal-title":"Leukemia"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s10529-006-9127-2","article-title":"Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR.","volume":"28","author":"S Fleige","year":"2006","journal-title":"Biotechnol Lett"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.","volume":"85","author":"P Rohon","year":"2010","journal-title":"Eur J Haematol"},{"key":"ref28","first-page":"7995","article-title":"Natural IgM antibodies and immunosurveillance mechanisms agains epithelial cancer cells in humans.","volume":"63","author":"S Brandlein","year":"2003","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.autrev.2008.03.012","article-title":"Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy?","volume":"7","author":"R Schwartz-Albiez","year":"2008","journal-title":"Autoimmun Rev"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.cmr.0000200490.62723.b0","article-title":"Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanoma.","volume":"16","author":"JM Larkin","year":"2006","journal-title":"Melanoma Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3233\/HAB-2002-11401","article-title":"Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients.","volume":"11","author":"S Br\u00e4ndlein","year":"2002","journal-title":"Hum Antib"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hon.705","article-title":"The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia.","volume":"21","author":"N Sato","year":"2003","journal-title":"Hematol Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.leukres.2010.01.012","article-title":"Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with imatinib.","volume":"34","author":"G Carulli","year":"2010","journal-title":"Leukemia Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"2","author":"BJ Druker","year":"1996","journal-title":"Nature Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukaemia through reversal of abnormally increased proliferation.","volume":"99","author":"MS Holtz","year":"2002","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells.","volume":"284","author":"MF Pittenger","year":"1999","journal-title":"Science"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.exphem.2008.12.008","article-title":"Effects of imatinib mesylate in osteoblastogenesis.","volume":"37","author":"D Tibullo","year":"2009","journal-title":"Exp Hematol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood.V97.1.198","article-title":"Synthesis and release of B-lymphocyte stimulator from myeloid cells.","volume":"97","author":"B Nardelli","year":"2001","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2009.017178","article-title":"Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4\/CXCL12 axis.","volume":"95","author":"F Vianello","year":"2010","journal-title":"Haematologica"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/sj.leu.2401875","article-title":"Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells.","volume":"14","author":"J D\u00fcrig","year":"2000","journal-title":"Leukemia"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0018925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T10:51:07Z","timestamp":1686048667000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0018925"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Dieli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,4,18]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,4,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0018925","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,18]]}}}